Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Acta cir. bras ; 29(7): 410-416, 07/2014. tab, graf
Article in English | LILACS | ID: lil-714571

ABSTRACT

PURPOSE: To evaluate the effects of exposure of enoxaparin and unfractionated heparin (UFH) in prophylactic and therapeutic doses on the fertility rates of pregnant healthy Wistar rats. METHODS: Enoxaparin and UFH were administered in prophylactic doses 1 mg/Kg/day 72 UI/Kg/day, and in therapeutic doses at 2 mg/kg/day 400UI/Kg/day. The rats were divided into five groups. The number of live and dead foetuses was quantified. The uterine horns were dissected and the presence of early and late reabsorptions (abortions) was determined. A p<0.05 was considered statistically significant. RESULTS: We did not observe statistically significant differences between groups when comparing the average weight of the foetuses and placentas, rate of female VS males, rates of pre-implantation loss (RPL), rates of efficiency implantation (REI), rates of post-implantation loss (RPIL) and rates of foetal viability (RFV). CONCLUSIONS: There was no significant effect on fertility with the use of anticoagulant drugs in pregnant healthy Wistar rats. .


Subject(s)
Animals , Female , Male , Pregnancy , Anticoagulants/administration & dosage , Enoxaparin/administration & dosage , Fertility/drug effects , Heparin/administration & dosage , Anticoagulants/adverse effects , Enoxaparin/adverse effects , Fetus/drug effects , Hemorrhage/chemically induced , Heparin/adverse effects , Placenta/drug effects , Random Allocation , Rats, Wistar , Reference Values , Time Factors , Thromboembolism/drug therapy
2.
Rev. Soc. Peru. Med. Interna ; 24(3): 138-141, jul.-sept. 2011. ilus
Article in Spanish | LIPECS, LILACS, LIPECS | ID: lil-609845

ABSTRACT

Se presenta un caso de hematoma retroperitoneal espontáneo asociado al uso de enoxaparina y aspirina a dosis terapéuticas, en una mujer de 75 años de edad que ingresa a la Unidad de Cuidados Intensivos con el diagnóstico de choque cardiogénico por infarto de miocardio son ST no elevado.


A spontaneous retroperitoneal hematoma case associated with use of enoxaparin and aspirin at therapeutic doses in a 75 year old-age woman who was admitted to the ICU with a diagnosis of cardiogenic shock due to non-ST elevated myocardial infarction.


Subject(s)
Humans , Female , Aged , Aspirin/adverse effects , Enoxaparin/adverse effects , Retroperitoneal Space/injuries , Hematoma , Peritoneum
4.
Rev. bras. cardiol. invasiva ; 16(2): 178-184, abr.-jun. 2008. tab, graf
Article in Portuguese | SES-SP, LILACS, SES-SP | ID: lil-498771

ABSTRACT

A heparina não fracionada (HNF) é terapia anticoagulante clássica na intervenção percutânea, prevenindo complicações trombóticas agudas. Estudos sugerem que as heparinas de baixo peso molecular podem ser uma alternativa segura e eficaz. Objetivos: Avaliar a segurança e a efetividade da enoxaparina (ENO) versus HNF em pacientes tratado por intervenção percutânea eletiva nas fases hospitalar (FH) e tardia (FT). Método: No período de outubro a novembro de 2004, incluímos 57 pacientes consecutivos tratados com ENO 0,75 mg/kg (G2) versus grupo controle de 143 pacientes tratados com UI/kg (G1) nos três meses prévios. Todos receberam stents não-farmacológicos e foram pré-tratados com aspirina mais ticlopidina. Analisamos as complicações vasculares (CV) e hemorrágicas (CH) e os eventos combinados (EC) morte, infarto agudo do miocárdio (IAM), acidente vascular encefálico (AVE) e revascularização de urgência (RU) na FH e EC morte, IAM, AVE e nova revascularização na FT. No G2-ENO, mensuramos o fator anti-Xa 10 minutos após bolus EV e no fim da intervenção percutânea. Resultados: A média de idade foi de 59,8 mais ou menos 9,8 anos, 30 por cento eram diabéticos...


Subject(s)
Humans , Male , Female , Middle Aged , Stents , Enoxaparin/administration & dosage , Enoxaparin/adverse effects , Heparin/administration & dosage , Heparin/adverse effects , Anticoagulants/administration & dosage
6.
Neurol India ; 2006 Dec; 54(4): 431-3
Article in English | IMSEAR | ID: sea-121183

ABSTRACT

Symptomatic hemorrhagic transformation is common in supratentorial and cerebellar infarction, but is rare in brainstem infarction. It is seldom reported in basilar artery occlusion. Although early arterial recanalization by thrombolytic agent has became the new trend of treatment, for some neurologists anticoagulant is still a conventional alternative treatment of basilar artery occlusion, especially in longer-existing ischemic deficits. We report a case of massive pontine hemorrhage associated with enoxaparin (low-molecular-weight heparin) treatment for basilar artery occlusion. On the basis of the clinical information and neuroimaging, an embolism was the most likely cause of stroke. The case presented herein adds massive pontine hemorrhagic transformation to the list of possible complications of anticoagulants for basilar artery occlusion. Apart from no evidence-based benefit in treatment of basilar artery occlusion, anticoagulant may contribute to devastating hemorrhagic transformation.


Subject(s)
Aged , Anticoagulants/adverse effects , Cerebral Hemorrhage/chemically induced , Enoxaparin/adverse effects , Humans , Male , Pons/pathology , Tomography, X-Ray Computed , Vertebrobasilar Insufficiency/drug therapy
7.
Rio de Janeiro; s.n; 2006. 82 p. tab.
Thesis in Portuguese | LILACS | ID: lil-499326

ABSTRACT

O desenvolvimento de um programa de farmacovigilância pode representar a melhoria da qualidade assistencial, também através de ações continuadas que monitorem parâmetros clínico/laboratoriais e forneçam retro-alimentação sobre a terapêuticamedicamentosa. De modo a estimular a implantação da farmacovigilância em umhospital da rede privada do Rio de Janeiro identificou-se o medicamento, enoxaparina sódica, e formulou-se um projeto de investigação de efeitos adversos nas unidades Emergência/Hemodinâmica e Coronariana do hospital. Revisou-se a literatura, por meio de busca nas bases Medline e Lilacs, para identificar indicações de uso, efeitos adversosmais freqüentes e fatores de risco para o aparecimento de reações adversas (RAM) à enoxaparina sódica. A seguir, elaborou-se um instrumento para a coleta dos dados e propôs-se o fluxo de encaminhamento das notificações, seguidos da análise e classificação das reações segundo a WHO-ART. O projeto incluiu também planejamento para cursos de capacitação em farmacovigilância e estruturação doprograma. Aplicou-se o pré-teste do instrumento durante 30 dias nas unidades. Coletaram-se dados referentes a variáveis demográficas, indicação para uso do medicamento, dose e medicamentos associados, existência de co-morbidades e fatoresde risco relacionados ao estilo de vida. Os dados clínicos foram obtidos a partir dos prontuários e exames laboratoriais e informações do serviço de hemoterapia. As informações consideradas relevantes foram avaliadas juntamente com outrosprofissionais de saúde. Foram coletados dados de 39 pacientes dos quais 24 da unidade coronariana e 15 da Emergência/Hemodinâmica. O instrumento mostrou-se de fácilaplicabilidade. A coleta mostrou que as variáveis eram passíveis de resgate nas fontes e que situações específicas poderiam ser descritas com base no relato, o que possibilitaria, no futuro, a análise de causalidade...


Subject(s)
Humans , Anticoagulants/adverse effects , Drug Monitoring , Enoxaparin/adverse effects , Hospitals, Private , Pharmacoepidemiology , Adverse Drug Reaction Reporting Systems , Brazil , Communication
10.
New Egyptian Journal of Medicine [The]. 2005; 33 (3): 135-142
in English | IMEMR | ID: emr-73885

ABSTRACT

The rapid progress in the field of interventional cardiology in the last few years necessitates a continuous search for the most safe and effective methods to gain an optimum results, either equipments or drugs. to examine the use of enoxaparin as an anticoagulant in elective PCI, and compare it with unfractionated heparin regarding the acute procedural complications and the immediate 24-hour post-PCI events. The study was conducted on 84 patients who were classified independently into 2 groups. 50 patients represent group [A], received IV single bolus of enoxaparin in a dose of 0.5mg/kg at the start of the procedure and 34 patients represent group [B], received the usual traditional dose of unfractionated heparin [10000-15000 units].All patients were prepared by clopidogrel or ticlopidin before PCI in addition to aspirin 150 mg daily.Follow up was done for all patients during the immediate 24 hours after PCI for death, myocardial infarction, myocardial ischemia requiring urget coronary intervention and cerobrovascular stroke. There was no statistical significant difference between the two groups regarding the type of vessels treated or number of stents placed. None of the patients of both groups experienced any of the following complications during the procedure or 24 hours after: major bleeding, myocardial infarction, myocardial ischemia requiring urgent surgical or repeat percutaneous coronary revascularization or death. The major difference between the two groups was the immediate sheath removal in the enoxaparin group, without sheath site complication [minor haematoma] which was observed in 9% of the UFH group. Angiographic complications were coronary artery dissection [in one patient in group A [2%] and 3 patients in group B [9%]] and acute closure of the culprit vessel [occurred in one patient in group A [2%] and none in group B. The results were quite encouraging, with no statistical differences between the two arms of the study regarding the acute complications and the clinical outcome. The use of enoxaparin in this reduced dose is feasible in elective PCI with adequate level of anticoagulation without need for monitoring its anticoagulant effect. The early sheath removal in group A necessitates further studies to assess its impact on the duration of hospital stay and the possibility of early discharge of the patients


Subject(s)
Humans , Male , Female , Heparin/adverse effects , Enoxaparin/adverse effects , Risk Factors , Smoking , Hypertension , Diabetes Mellitus , Hyperlipidemias , Treatment Outcome
11.
Rev. argent. anestesiol ; 56(2): 107-8, mar.-abr. 1998.
Article in Spanish | LILACS | ID: lil-233746

ABSTRACT

Hasta el mes de noviembre de 1997 se recibieron más de 30 informes voluntarios describiendo pacientes que desarrollaron hematomas epidurales o espinales con el uso simultáneo de enoxaparina sódica y anestesia espinal/epidural o punción dural. La mayoría de los hematomas epidurales o espinales causaron lesión neurológica, incluyendo parálisis prolongada o permanente. Apróximadamente el 75 por ciento de los pacientes fueron mujeres de edad avanzada que se sometieron a cirugía ortopédica. En este momento la FDA considera que los médicos deben tener presentes las siguientes consideraciones si utilizan estos productos: Cuando se emplea anestesia neuraxial (anestesia epidural/espinal) o punción espinal, los pacientes tratados o que van a ser tratados con anticoagulantes del tipo heparina de bajo peso molecular o heparoinoides para prevenir complicaciones tromboembólicas, tienen riesgo de desarrollar hematoma epidural o espinal que puede producir parálisis prolongada o permanente. El riesgo de estos episodios se incrementa con el uso de catéteres epidurales continuos para administrar analgesia o por el uso concomitante de drogas que afectan la hemostasis como las drogas antiinflamatorias no esteroides (DAINES), los inhibidores de las plaquetas u otros anticoagulantes. El riesgo también parece incrementarse con la punción espinal o epidural traumática o repetida. Se debe monitorear con frecuencia a los pacientes por signos y síntomas de deficiencia neurológica. Si se observa compromiso neurológico, es necesario un tratamiento urgente. Los médicos deben considerar en su totalidad el beneficio potencial versus el riesgo antes de la intervención neuraxial en los pacientes que recibieron o recibirán anticoagulantes para la tromboprofilaxis.


Subject(s)
Humans , Female , Aged , Anesthesia, Epidural , Hematoma, Epidural, Cranial/complications , Heparin, Low-Molecular-Weight/adverse effects , Spinal Puncture , United States Food and Drug Administration , Enoxaparin/adverse effects , Neurologic Manifestations
SELECTION OF CITATIONS
SEARCH DETAIL